发布求助
文献互助 智能选刊 最新文献

Nature Reviews Clinical Oncology最新文献

筛选
英文 中文
Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-02-10 DOI: 10.1038/s41571-025-00993-4
Rawan G. Faramand, Frederick L. Locke
{"title":"Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL","authors":"Rawan G. Faramand, Frederick L. Locke","doi":"10.1038/s41571-025-00993-4","DOIUrl":"10.1038/s41571-025-00993-4","url":null,"abstract":"Recent data from the FELIX trial evaluating obecabtagene autoleucel in patients with relapsed and/or refractory B acute lymphoblastic leukaemia (R/R B-ALL) suggest that this novel intermediate-affinity CD19-directed chimeric antigen receptor (CAR) T cell therapy is associated with a reduced incidence of severe immune-mediated toxicities compared with other commercially available CAR T cell products. The increasing number of therapies available for B-ALL makes treatment selection and sequencing of therapies increasingly challenging.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 3","pages":"161-162"},"PeriodicalIF":81.1,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143375308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AI accurately identifies targetable alterations in lung cancer histological images
IF 78.8 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-02-10 DOI: 10.1038/s41571-025-00999-y
Hortense Le, Aristotelis Tsirigos
{"title":"AI accurately identifies targetable alterations in lung cancer histological images","authors":"Hortense Le, Aristotelis Tsirigos","doi":"10.1038/s41571-025-00999-y","DOIUrl":"https://doi.org/10.1038/s41571-025-00999-y","url":null,"abstract":"DeepGEM, an artificial intelligence (AI)-based model, accurately predicts the presence of key genomic alterations in histological slides prepared from samples obtained from patients with lung cancer. This approach provides a cost-effective alternative to genomic testing, generates spatial mutation maps and might support personalized treatment strategies. Validated in diverse datasets, DeepGEM highlights the potential of AI to transform precision oncology and improve global healthcare equity.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"84 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143375171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas
IF 78.8 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-02-07 DOI: 10.1038/s41571-025-00998-z
Diana Romero
{"title":"Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas","authors":"Diana Romero","doi":"10.1038/s41571-025-00998-z","DOIUrl":"https://doi.org/10.1038/s41571-025-00998-z","url":null,"abstract":"<p>Patients with HER2-negative advanced-stage gastric or gastro-oesophageal junction (G/GEJ) adenocarcinomas typically receive chemotherapy with or without an anti-PD-1 antibody as first-line treatment. Now, data from the phase III COMPASSION-15 trial show that combination of the PD-1 × CTLA4 bispecific antibody cadonilimab plus chemotherapy is also efficacious in this setting.</p><p>In this trial, conduced in China, 610 patients were randomly allocated (1:1) to receive chemotherapy (oxaliplatin–capecitabine) plus either cadonilimab or placebo. Overall survival (OS) was the primary end point.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"78 5 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143367370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transanal TME noninferior to the laparoscopic approach
IF 78.8 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-02-06 DOI: 10.1038/s41571-025-00997-0
Peter Sidaway
{"title":"Transanal TME noninferior to the laparoscopic approach","authors":"Peter Sidaway","doi":"10.1038/s41571-025-00997-0","DOIUrl":"https://doi.org/10.1038/s41571-025-00997-0","url":null,"abstract":"<p>Patients with resectable mid–low rectal cancers often undergo total mesorectal excision (TME) surgery. Over the past decade, considerable research interest has been focused on minimally invasive TME procedures that might offer improved perioperative outcomes and preservation of sphincter function, including laparoscopic and transanal approaches. Despite some evidence of an increased risk of local recurrence with the transanal approach, only limited data on long-term outcomes are available. Now, data from the phase III TaLaR trial indicate similar 3-year survival outcomes among patients undergoing these procedures.</p><p>A total of 1,115 patients with stage I–III mid–low rectal cancer (located within 10 cm of the rectal verge) requiring TME surgery were randomly assigned (1:1) to undergo transanal or laparoscopic TME across 16 centres in China. Noninferior 3-year disease-free survival (DFS) was the primary end point.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"14 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143258062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
International approvals of cilta-cel: a lens on CAR T cell regulation
IF 78.8 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-02-06 DOI: 10.1038/s41571-025-00996-1
Chenghao Ge, Chen Yin, Xiaoyuan Chen
{"title":"International approvals of cilta-cel: a lens on CAR T cell regulation","authors":"Chenghao Ge, Chen Yin, Xiaoyuan Chen","doi":"10.1038/s41571-025-00996-1","DOIUrl":"https://doi.org/10.1038/s41571-025-00996-1","url":null,"abstract":"The BCMA-targeted chimeric antigen receptor (CAR) T cell therapy ciltacabtagene autoleucel (cilta-cel) has demonstrated exceptional efficacy in studies conducted worldwide, which has resulted in regulatory approvals in &gt;40 countries. Herein, we examine the regulatory pathways that led to its approval in different regions, focus on challenges in clinical development and regulatory submission, and provide insight into strategies for advancing innovative cell therapies.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"9 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143257964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck
IF 78.8 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-02-03 DOI: 10.1038/s41571-025-00986-3
Jia Luo, Justin A. Bishop, Steven G. DuBois, Glenn J. Hanna, Lynette M. Sholl, Edward B. Stelow, Lester D. R. Thompson, Geoffrey I. Shapiro, Christopher A. French
{"title":"Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck","authors":"Jia Luo, Justin A. Bishop, Steven G. DuBois, Glenn J. Hanna, Lynette M. Sholl, Edward B. Stelow, Lester D. R. Thompson, Geoffrey I. Shapiro, Christopher A. French","doi":"10.1038/s41571-025-00986-3","DOIUrl":"https://doi.org/10.1038/s41571-025-00986-3","url":null,"abstract":"<p>In the past two decades, treatment for non-small-cell lung cancers (NSCLCs) and head and neck squamous cell carcinoma (HNSCC) has advanced considerably, owing largely to the characterization of distinct oncological subtypes, the development of targeted therapies for each subtype and the advent of immunotherapy. Data emerging over the past two decades suggest that NUT carcinoma, a highly aggressive malignancy driven by a NUT fusion oncoprotein and arising in the lungs, head and neck, and rarely in other sites, is a squamous cell carcinoma (SCC) based on transcriptional, histopathological, cell-of-origin and molecular characteristics. NUT carcinoma has an estimated incidence of 1,400 cases per year in the United States, surpassing that of some rare NSCLC and HNSCC subtypes. However, NUT carcinoma is currently not recognized as an SCC of the lungs or head and neck. The orphan classification of NUT carcinoma as a distinct entity leads to a lack of awareness of this malignancy among oncologists and surgeons, despite early diagnosis being crucial for this cancer type with a median survival of only ~6.5 months. Consequently, NUT carcinoma is underdiagnosed and often misdiagnosed, resulting in limited research and progress in developing effective treatments in one of the most aggressive forms of lung and head and neck cancer. With a growing number of targeted agents that can potentially be used to treat NUT carcinoma, improved recognition through reclassification and inclusion of NUT carcinoma as a squamous NSCLC or an HNSCC when arising in these locations will accelerate the development of effective therapies for this disease. Thus, in the Perspective, we propose such a reclassification of NUT carcinoma as an SCC and discuss the supporting evidence.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"20 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143083319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC
IF 78.8 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-01-31 DOI: 10.1038/s41571-025-00995-2
David Killock
{"title":"Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC","authors":"David Killock","doi":"10.1038/s41571-025-00995-2","DOIUrl":"https://doi.org/10.1038/s41571-025-00995-2","url":null,"abstract":"<p>Two multimodal treatment strategies, perioperative chemotherapy and preoperative chemoradiotherapy, have been shown to improve overall survival (OS) compared to surgery alone in patients with locally advanced oesophageal adenocarcinoma (EAC); however, the optimal approach has been unclear. Newly published results from the phase III ESOPEC trial demonstrate the superiority of the perioperative strategy.</p><p>In ESOPEC, 438 patients with resectable cT1–4aN+ or cT2–4aN0 EAC were randomly assigned (1:1) to receive four preoperative and four postoperative cycles of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) or preoperative radiotherapy (41.4 Gy in 23 fractions) plus concurrent weekly carboplatin and paclitaxel. OS was the primary end point.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"7 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143071853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thermal ablation is safer than resection of colorectal liver lesions
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-01-30 DOI: 10.1038/s41571-025-00994-3
Diana Romero
{"title":"Thermal ablation is safer than resection of colorectal liver lesions","authors":"Diana Romero","doi":"10.1038/s41571-025-00994-3","DOIUrl":"10.1038/s41571-025-00994-3","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 3","pages":"158-158"},"PeriodicalIF":81.1,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143056197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transforming paediatric AML trials: from failing one-size-fits-all methods to precision oncology
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-01-27 DOI: 10.1038/s41571-025-00989-0
Branko Cuglievan, Vivek Subbiah
{"title":"Transforming paediatric AML trials: from failing one-size-fits-all methods to precision oncology","authors":"Branko Cuglievan,&nbsp;Vivek Subbiah","doi":"10.1038/s41571-025-00989-0","DOIUrl":"10.1038/s41571-025-00989-0","url":null,"abstract":"Paediatric acute myeloid leukaemia (AML) highlights the challenges of drug development for rare diseases, in which limited patient numbers and substantial heterogeneity hinder progress. Traditional one-size-fits-all randomized trials are ineffective. Nonetheless, tailored therapies and biomarker-driven studies can improve outcomes and transform the treatment of paediatric patients with AML and potentially other rare cancers.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 3","pages":"155-156"},"PeriodicalIF":81.1,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143049697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early promising results with addition of an ICI and an anti-angiogenic to TACE
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-01-27 DOI: 10.1038/s41571-025-00990-7
Diana Romero
{"title":"Early promising results with addition of an ICI and an anti-angiogenic to TACE","authors":"Diana Romero","doi":"10.1038/s41571-025-00990-7","DOIUrl":"10.1038/s41571-025-00990-7","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 3","pages":"157-157"},"PeriodicalIF":81.1,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143049986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信